Non-small cell lung cancer is a condition wherein there is unwanted and uncontrolled cell growth in lung tissues. The non-small cell lung cancer market is likely to witness expansion. This is anticipated to happen at around 4.85 percentage CAGR by the end of 2019.
Lung cancer is one of the most common cancers. It happens due to changing lifestyles, air pollution and increasing smoking habits. Some of the most common symptoms of non-small cell lung cancer include coughing up blood, chest pain, bone pain and others.
The non-small cell lung cancer market can be divided into types and geographies. On the basis of types, the market is bifurcated into histology and treatment. The histology market can be divided further into large cell carcinoma, squamous cell carcinoma (SCC) and adenocarcinoma. Large cell carcinoma can occur in any part of the lung and grows fastest.
It is an incurable form of cancer. SCC occurs near the center of lungs, close to bronchus in squamous cells. Adenocarcinoma occurs in mucous secretion cells and grows slowly compared to the other two. The treatment non-small cell lung cancer market can be divided further into chemotherapy, radiation and surgery. Chemotherapy is a widely recognized form of treatment for lung and other cancers.
Radiation is used during the first or second stages when surgery is not possible. Surgery consists of wedge resection, lobectomy (lung section removal) and pneumonectomy (complete lung removal). Geographically, the non-small cell lung cancer market can be segmented into four key regions, including North America, Europe, Asia Pacific and ROW (rest of the world).
North America is predicted to be the largest non-small cell lung cancer market. It is followed by Europe and Asia Pacific.
Posted on Apr 17, 2015 | Category Healthcare